Biotech Finance & Funding Focus Day

26th February 2008

8.00 Registration & Coffee

8.50 Chairman’s Opening Remarks

Hubert Birner,
General Partner,
TVM Capital

9.00 Analysing The Current And Future Landscape Of Biotech Funding

Ton Gardeniers,
Global Head of Healthcare, Investment Banking,
Managing Director,
ABN AMRO

9.40 Panel Discussion: Assessing The Viability Of Different Options For Funding To Avoid The Funding Gap

Jim Webster,
Managing Partner,
Capital Royalty L.P.

Susan Searle,
CEO,
Imperial Innovations

Chandra Leo,
Investment Advisor,
HBM

Franco Cozzani,
Eurostars

10.20 Maximising The Appeal Of Your Research To Potential Investors By Establishing An Appropriate Commercial Framework

Dr Christine Lemke,
VP Business Development,
Medigene

11.00 Morning Coffee

11.30 A-Round Case Study: Preparing A Robust Case To Attract High Levels Of Series A Funding

Urs Tuor,
Head of Business Development,
Glycovaxyn

12.10 B-Round Case Study: Mapping Out The Development Of Your Asset To Ensure Substantial B-Round Funding

Gun-Britt Fransson,
CEO,
Alligator Bioscience

12.50 Lunch

14.00 Panel Discussion: Examining The Evolving Relationship Between VCs And Pharma Companies In Driving Creative Biotech Deal Structures

Antoine Papiernik,
Managing Partner,
Sofinnova Partners

Roland Kozlowski,
CEO,
Lectus Therapeutics

14.40 Determining When You Reach The Trade Sale/IPO Crossroads And Establishing The Best Fit Option For Your Organisation

Alexandra Goll,
General Partner,
TVM Capital

15.20 Afternoon Coffee

15.50 Successfully Planning And Executing A Large-Scale IPO: A Case Study On Addex

Tim Dyer,
CFO,
Addex

16.30 End Of Biotech Finance & Funding Focus Day